Dermatologia

Amat-Samaranch V., Puig L. (2020) Safety of calcipotriene and betamethasone dipropionate foam for the treatment of psoriasis. EXPERT OPIN DRUG SAF, 19 (4), 423-432.

IF: 4,250

Armstrong A., Paul C., Puig L., Boehncke W.H., Freeman M., Torii H., Papp K., Griffiths C.E.M., Blauvelt A., Reich K., Gooderham M., Terui T., Renda L., Agada N., Xu W., Gallo G., Lebwohl M.G. (2020) Safety of Ixekizumab Treatment for up to 5 Years in Adult Patients with Moderate-to-Severe Psoriasis: Results from Greater Than 17,000 Patient-Years of Exposure. DERMATOLOGY THER, 10 (1), 133-150.

IF: 3,264

Armstrong A.W., Puig L., Joshi A., Skup M., Williams D., Li J., Betts K.A., Augustin M. (2020) Comparison of Biologics and Oral Treatments for Plaque Psoriasis: A Meta-analysis. JAMA DERMATOL, 156 (3), 258-269.

IF: 10,282

Bronckers I.M.G.J., Paller A.S., West D.P., Lara-Corrales I., Tollefson M.M., Tom W.L., Hogeling M., Belazarian L., Zachariae C., Mahe E., Siegfried E., Blume-Peytavi U., Szalai Z., Vleugels R.A., Holland K., Murphy R., Puig L., Cordoro K.M., Lambert J., Alexopoulos A., Mrowietz U., Kievit W., Seyger M.M.B. (2020) A Comparison of Psoriasis Severity in Pediatric Patients Treated with Methotrexate vs Biologic Agents. JAMA DERMATOL, 156 (4), 384-392.

IF: 10,282

Cork M.J., Eckert L., Simpson E.L., Armstrong A., Barbarot S., Puig L., Girolomoni G., de Bruin-Weller M., Wollenberg A., Kataoka Y., Remitz A., Beissert S., Mastey V., Ardeleanu M., Chen Z., Gadkari A., Chao J. (2020) Dupilumab improves patient-reported symptoms of atopic dermatitis, symptoms of anxiety and depression, and health-related quality of life in moderate-to-severe atopic dermatitis: analysis of pooled data from the randomized trials SOLO 1 and SOLO 2. J DERMATOL TREAT, 31 (6), 606-614.

IF: 3,359

Cubillos-Zapata C., Martinez-Garcia M.A., Diaz-Garcia E., Jaureguizar A., Campos-Rodriguez F., Sanchez-de-la-Torre M., Nagore E., Martorell-Calatayud A., Blasco L.H., Pastor E., Abad-Capa J., Montserrat J.M., Cabriada-Nuno V., Cano-Pumarega I., Corral-Penafiel J., Arias E., Mediano O., Somoza-Gonzalez M., Dalmau-Arias J., Almendros I., Farre R., Lopez-Collazo E., Gozal D., Garcia-Rio F. (2020) Obesity attenuates the effect of sleep apnea on active TGF-ß1 levels and tumor aggressiveness in patients with melanoma. SCI REP-UK, 10 (1), -.

IF: 4,379

Cubiro X., Rozas-Munoz E., Castel P., Roe Crespo E., Garcia-Melendo C., Puig L., Baselga E. (2020) Clinical and genetic evaluation of six children with diffuse capillary malformation and undergrowth. PEDIATR DERMATOL, 37 (5), 833-838.

IF: 1,588

de Bruin-Weller M., Gadkari A., Auziere S., Simpson E.L., Puig L., Barbarot S., Girolomoni G., Papp K., Pink A.E., Saba G., Werfel T., Eckert L. (2020) The patient-reported disease burden in adults with atopic dermatitis: a cross-sectional study in Europe and Canada. J EUR ACAD DERMATOL, 34 (5), 1026-1036.

IF: 6,166

del Alcazar E., Ferran M., Lopez-Ferrer A., Notario J., Vidal D., Riera J., Aparicio G., Gallardo F., Vilarrasa E., Alsina M., Puig L., Ferrandiz C., Carrascosa J.M. (2020) Effectiveness and safety of ustekinumab 90 mg in patients weighing 100 kg or less: a retrospective, observational, multicenter study. J DERMATOL TREAT, 31 (3), 222-226.

IF: 3,359

del Alcazar E., Suarez-Perez J.A., Armesto S., Rivera R., Herrera-Acosta E., Herranz P., Martin I., Montesinos E., Hospital M., Vilarrasa E., Ferran M., Ruiz-Villaverde R., Sahuquillo-Torralba A., Ruiz-Genao D.P., Perez-Barrio S., Munoz C., Llamas M., Valenti F., Mitxelena M.J., Lopez-Ferrer A., Carretero G., Vidal D., Mollet J., Belinchon I., Carrascosa J.M. (2020) Real-world effectiveness and safety of apremilast in psoriasis at 52 weeks: a retrospective, observational, multicentre study by the Spanish Psoriasis Group. J EUR ACAD DERMATOL, 34 (12), 2821-2829.

IF: 6,166

Diels J., Thilakarathne P., Cameron C., McElligott S., Schubert A., Puig L. (2020) Adjusted treatment COMPArisons between guSelkumab and uStekinumab for treatment of moderate-to-severe plaque psoriasis: the COMPASS analysis. BRIT J DERMATOL, 183 (2), 276-284.

IF: 9,302

Fernandez-de-Misa R., Hernandez-Machin B., Combalia A., Garcia Muret M.P., Servitje O., Muniesa C., Gallardo F., Pujol R.M., Marti R.M., Ortiz-Brugues A., Maronas-Jimenez L., Ortiz-Romero P.L., Blanch Rius L., Izu R., Roman C., Canueto J., Blanes M., Morillo M., Bastida J., Penate Y., Perez Gala S., Espinosa Lara P., Perez Gil A., Estrach T. (2020) Prognostic factors in patients with primary cutaneous anaplastic large cell lymphoma: a multicentric, retrospective analysis of the Spanish Group of Cutaneous Lymphoma. J EUR ACAD DERMATOL, 34 (4), 762-768.

IF: 6,166

Fernandez-Figueras M.-T., Puig L. (2020) The Role of Epithelial-to-Mesenchymal Transition in Cutaneous Squamous Cell Carcinoma: Epithelial-to-Mesenchymal Transition in Cutaneous SCC. CURR TREAT OPTION ON, 21 (6), -.

IF: 5,036

Gely C., Marin L., Gordillo J., Manosa M., Bertoletti F., Canete F., Gonzalez-Munoza C., Calafat M., Domenech E., Garcia-Planella E. (2020) Impact of pain associated with the subcutaneous administration of adalimumab Impacto del dolor asociado a la administración subcutánea de adalimumab. GASTROENT HEPAT-BARC, 43 (1), 9-13.

IF: 2,102

Gonzalez-Manso A., Agut-Busquet E., Romani J., Vilarrasa E., Bittencourt F., Mensa A., Canto E., Arostegui J.I., Vidal S., Hidradenitis Suppurativa: Proposal of Classification in Two Endotypes with Two-Step Cluster Analysis (2020) DERMATOLOGY.

IF: 5,366

Iznardo H., Roe E., Puig L., Vikula M., Lopez-Sanchez C., Baselga E. (2020) Good response to pulsed dye laser in patients with capillary malformation-arteriovenous malformation syndrome (CM-AVM). PEDIATR DERMATOL, 37 (2), 342-344.

IF: 1,588

Iznardo H., Puig L. (2020) The safety of brodalumab for the treatment of psoriasis. EXPERT OPIN DRUG SAF, 19 (4), 365-372.

IF: 4,250

Iznardo H., Garcia-Melendo C., Yelamos O. (2020) Lentigo maligna: Clinical presentation and appropriate management. CLIN COSMET INV DERM, 13 (), 837-855.

IF: 2,489

Lopez-Sanchez C., Iznardo H., Mozos A., Flores-Climente V., Puig L. (2020) Purple ulcerated nodules in a middle-aged man. INT J DERMATOL, 59 (4), e96-e98.

IF: 2,736

Lopez-Sanchez C., Puig L. (2020) Guselkumab in the treatment of moderate-to-severe plaque psoriasis. IMMUNOTHERAPY-UK, 12 (6), 355-371.

IF: 4,196

Marron S.E., Miranda-Sivelo A., Tomas-Aragones L., Rodriguez-Cerdeira C., Tribo-Boixaro M.J., Garcia-Bustinduy M., Gracia-Cazana T., Ros-Abarca S., Roe-Crespo E., Diaz-Diaz R.M., Brufau-Redondo C., Martinez-Gonzalez M.C., Guerra-Tapia A., Gonzalez-Guerra E., Puig L. (2020) Body dysmorphic disorder in patients with acne: a multicentre study. J EUR ACAD DERMATOL, 34 (2), 370-376.

IF: 6,166

Mir-Bonafe J.F., Rozas-Munoz E., Pedemonte-Sarrias E., Mir-Bonafe M., Mir-Bonafe J.M., Piquero-Casals J., Puig L. (2020) Psoriasis precipitated by timolol eye drops. A series of eight cases. AUSTRALAS J DERMATOL, 61 (1), e91-e93.

IF: 2,875

Misery L., Weisshaar E., Brenaut E., Evers A.W.M., Huet F., Stander S., Reich A., Berardesca E., Serra-Baldrich E., Wallengren J., Linder D., Fluhr J.W., Szepietowski J.C., Maibach H., Honari G., Le Gall-Ianotto C., Takamori K., Richters R. (2020) Pathophysiology and management of sensitive skin: position paper from the special interest group on sensitive skin of the International Forum for the Study of Itch (IFSI). J EUR ACAD DERMATOL, 34 (2), 222-229.

IF: 6,166

Nogueira M., Puig L., Torres T. (2020) JAK Inhibitors for Treatment of Psoriasis: Focus on Selective TYK2 Inhibitors. DRUGS, 80 (4), 341-352.

IF: 9,546

Pereira M.P., Ziehfreund S., Rueth M., Ewering T., Legat F.J., Lambert J., Elberling J., Misery L., Brenaut E., Papadavid E., Garcovich S., Evers A.W.M., Halvorsen J.A., Szepietowski J.C., Reich A., Goncalo M., Lvov A., Bobko S., Serra-Baldrich E., Wallengren J., Savk E., Leslie T., Stander S., Zink A., Google search trends for itch in Europe: a retrospective longitudinal study (2020) J EUR ACAD DERMATOL.

IF: 6,166

Pereira M.P., Hoffmann V., Weisshaar E., Wallengren J., Halvorsen J.A., Garcovich S., Misery L., Brenaut E., Savk E., Potekaev N., Lvov A., Bobko S., Szepietowski J.C., Reich A., Bozek A., Legat F.J., Metz M., Streit M., Serra-Baldrich E., Goncalo M., Storck M., Greiwe I., Nau T., Steinke S., Dugas M., Stander S., Zeidler C., Dalgard F., Elberling J., Forner C., Leslie T., Riepe C., Schneider G., Stander H. (2020) Chronic nodular prurigo: clinical profile and burden. A European cross-sectional study. J EUR ACAD DERMATOL, 34 (10), 2373-2383.

IF: 6,166

Puig L., Lomaga M., Hollister K., Dutronc Y., Berggren L., Van De Kerkhof P. (2020) An analysis of patient-reported outcomes in ixora-s: Comparing ixekizumab and ustekinumab over 52 weeks in moderate-to-severe psoriasis. ACTA DERM-VENEREOL, 100 (19), 1-7.

IF: 4,437

Puig L., Carrascosa J.-M., Dauden E., Sulleiro S., Guisado C. (2020) Drug survival of conventional systemic and biologic therapies for moderate-to-severe psoriasis in clinical practice in Spain: prospective results from the SAHARA study. J DERMATOL TREAT, 31 (4), 344-351.

IF: 3,359

Puig L., Tsai T.-F., Bhutani T., Uy J., Ramachandran P., Song M., You Y., Gooderham M., Lebwohl M. (2020) Safety in moderate-to-severe plaque psoriasis patients with latent tuberculosis treated with guselkumab and anti-tuberculosis treatments concomitantly: results from pooled phase 3 VOYAGE 1 & VOYAGE 2 trials. J EUR ACAD DERMATOL, 34 (8), 1744-1749.

IF: 6,166

Puig L., Lebwohl M., Bachelez H., Sobell J., Jacobson A.A. (2020) Long-term efficacy and safety of brodalumab in the treatment of psoriasis: 120-week results from the randomized, double-blind, placebo- and active comparator–controlled phase 3 AMAGINE-2 trial. J AM ACAD DERMATOL, 82 (2), 352-359.

IF: 11,527

Puig L. (2020) The safety of ixekizumab in psoriasis drug therapy. EXPERT OPIN DRUG SAF, 19 (2), 117-130.

IF: 4,250

Reich K., Puig L., Szepietowski J.C., Paul C., Lacour J.P., Tsianakas A., Sieder C., Rissler M., Pournara E., Orsenigo R. (2020) Secukinumab dosing optimization in patients with moderate-to-severe plaque psoriasis: results from the randomized, open-label OPTIMISE study. BRIT J DERMATOL, 182 (2), 304-315.

IF: 9,302

Reich K., Warren R.B., Iversen L., Puig L., Pau-Charles I., Igarashi A., Ohtsuki M., Falques M., Harmut M., Rozzo S., Lebwohl M.G., Cantrell W., Blauvelt A., Thaci D. (2020) Long-term efficacy and safety of tildrakizumab for moderate-to-severe psoriasis: pooled analyses of two randomized phase III clinical trials (reSURFACE 1 and reSURFACE 2) through 148 weeks. BRIT J DERMATOL, 182 (3), 605-617.

IF: 9,302

Rivera R., Velasco M., Vidal D., Carrascosa J.M., Dauden E., Vilarrasa E., Notario J., Ruiz-Villaverde R., Yanguas I., Garcia-Latasa F.J., Ferran M., Lazaro-Simo A., de la Cueva P., Salgado-Boquete L., Belinchon I. (2020) The effectiveness and safety of ixekizumab in psoriasis patients under clinical practice conditions: A Spanish multicentre retrospective study. DERMATOL THER, 33 (6), -.

IF: 2,851

Rodriguez-Jimenez P., Jimenez Y.D., Reolid A., Sanmartin-Jimenez O., Garces J.R., Rodriguez-Prieto M.A., Medrano R.M., Vilarrasa E., de Eusebio-Murillo E., Redondo P., Ciudad-Blanco C., Morales-Gordillo V., Toll-Abello A., Artola-Igarza J.L., Pacheco M.L.A., Markixana I.A., Fernandez R.S., Rubio A.A., Vazquez-Veiga H., Florez-Menendez A., de la Cueva Dobao P., Botella-Estrada R., Garcia-Bracamonte B., Carnero-Gonzalez L., Ruiz-Salas V., Sanchez-Sambucety P., Lopez-Estebaranz J.L., Gil P., Barchino L., Arenal M.M., Ocerin-Guerra I., Hueso L., Seoane-Pose M.J., Gonzalez-Sixto B., Cano-Martinez N., Escutia-Munoz B., Ortiz-Romero P.L., Garcia-Doval I., Descalzo M.A. (2020) State of the art of Mohs surgery for rare cutaneous tumors in the Spanish Registry of Mohs Surgery (REGESMOHS). INT J DERMATOL, 59 (3), 321-325.

IF: 2,736

Romani J., Vilarrasa E., Martorell A., Fuertes I., Ciudad C., Molina-Leyva A. (2020) Ustekinumab with intravenous infusion: Results in hidradenitis suppurativa. DERMATOLOGY, 236 (1), 21-24.

IF: 5,366

Rozas Munoz E., Mir-Bonafe J.F., Mozos A., Szafranska J., Puig L. (2020) Asymptomatic Exophytic Plaques on the Penis of a Patient With HIV Infection: Answer. AM J DERMATOPATH, 42 (3), 218-219.

IF: 1,533

Rozas-Munoz E., Mir-Bonafe J.F., Mozos A., Szafranska J., Puig L. (2020) Asymptomatic Exophytic Plaques on the Penis of a Patient With HIV Infection: Challenge. AM J DERMATOPATH, 42 (3), e28-e29.

IF: 1,533

Rozas-Munoz E., Mir-Bonafe J.F., Mozos A., Planas-Ciudad S., Garcia-Muret M.P. (2020) A 70-Year-Old Man With Raspberry-Like Tumors on the Nipples: Challenge. AM J DERMATOPATH, 42 (9), e122-e123.

IF: 1,533

Rozas-Munoz E., Mir-Bonafe J.F., Mozos A., Planas-Ciudad S., Garcia-Muret M.P. (2020) A 70-Year Old Man With Raspberry-Like Tumors on the Nipples: Answer. AM J DERMATOPATH, 42 (9), 708-709.

IF: 1,533

Ruiz de Morales J.M.G., Puig L., Dauden E., Canete J.D., Pablos J.L., Martin A.O., Juanatey C.G., Adan A., Montalban X., Borruel N., Orti G., Holgado-Martin E., Garcia-Vidal C., Vizcaya-Morales C., Martin-Vazquez V., Gonzalez-Gay M.A. (2020) Critical role of interleukin (IL)-17 in inflammatory and immune disorders: An updated review of the evidence focusing in controversies. AUTOIMMUN REV, 19 (1), -.

IF: 9,754

Sanz-Martinez M.T., Moga E., Sanchez Martinez M.A., Zamora Atenza C., Vidal S., Juarez C., Puig L. (2020) High Levels of Platelet-Lymphocyte Complexes in Patients with Psoriasis Are Associated with a Better Response to Anti–TNF-α Therapy. J INVEST DERMATOL, 140 (6), 1176-1183.

IF: 8,551

Serra E., Campo C., Novak Z., Majorek-Olechowska B., Pulka G., Garcia-Bea A., Labeaga L. (2020) Efficacy and safety of bilastine in reducing pruritus in patients with chronic spontaneous urticaria and other skin diseases: an exploratory study. J DERMATOL TREAT, 31 (3), 270-278.

IF: 3,359

Torres T., Puig L. (2020) Managing Cutaneous Immune-Mediated Diseases During the COVID-19 Pandemic. AM J CLIN DERMATOL, 21 (3), 307-311.

IF: 7,403

Zouboulis C.C., Hansen H., Caposiena Caro R.D., Damiani G., Delorme I., Pascual J.C., Reguiai Z., Trigoni A., Vilarrasa E., Roldan F.A. (2020) Adalimumab dose intensification in recalcitrant hidradenitis suppurativa/Acne inversa. DERMATOLOGY, 236 (1), 25-30.

IF: 5,366